fashion -WSS

fashion

author：fashion 2025-10-02 04:08:12 - browse：59123

Layoff concept illustration of empty desks and people walking away. — Adobe

Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular condensates, laid off 15% of its staff on Tuesday and acknowledged that a pair of collaboration deals with pharma companies had fallen apart.

The downsizing is temporary, CEO Ameet Nathwani told STAT. The company needed to hire new employees with expertise to help move the company’s first drugs into clinical trials and expand its AI capabilities. And with funding for early-stage biotechs still sparse, leadership opted to cut some positions and use the savings to fill new ones over the coming months. Roughly 20 positions were cut.

“We talked to investors right now [about raising more money], and they think that the environment for a preclinical company — it’s not even worth having that discussion,” Nathwani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Federal weight loss drug coverage is 30 years out of date

WSS

U.K. sequencing study surfaces new findings about tumor DNA

What will save rural psychiatry services? Higher Medicaid payments

How a scoliosis diagnosis changed the life of one young dancer

White House finalizes ITC's import ban of latest Apple Watches

Average age of first period drops to 11.9 years, study shows

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

focus

fashion

leisure time

Walensky prepares to leave CDC — and Congress — behind

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Jerome Adams on the need for new antivirals for Covid

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

The high cost of giving birth even with insurance

Focused ultrasound for uterine fibroids: an uphill battle

Psychedelics group wrestles with new pharma identity

Morgan Health, with ambitious aims, wants you to know it’s still here

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Feng Zhang, Grail founder join forces on new gene editing startup

explore

Startling documents reveal new facets of Sacklers' opioid empire

The biotech scorecard for Q1: 17 stock

Federal weight loss drug coverage is 30 years out of date

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Ahead of JPM, here's who's profiting most in health care

focus

leisure time

Wikipedia

focus